Ucbbiopharma Srl

Ucb Biopharma Sprl

Ucb Pharma, S.a.

Other

Celltech R&d Limited

Terence Seward Baker

Alastair David Griffiths Lawson

Patrick Downey

Ralph Adams

Kerry Louise Tyson

Helene Margaret Finney

David James McMillan

David Edward Ormonde Knight

Marc Roger De Ryck

Georges Mairet-Coello

Jean-Philippe Courade

Karen Margrete Miller

Christian Gilbert J Wolff

Timothy John Norman

Daniel John Lightwood

Xiaofeng Liu

Robert Anthony Griffin

Lorenzo De Lichtervelde

Michael Anthony William Eaton

David Parker

Marco Kriek

Catherine Fiona Catterall

Peter Charles Elliott

Andrew Neil Charles Weir

John Robert Porter

David Paul Humphreys

John Robert Adair

David G Parker

Richard David Taylor

Raymond John Owens

Catherine McKay

Alan Howard Lyons

William F Couslon

John G Simpson

Stephen R Abbott

Michael J Powell

John F Wright

James Petrie Turner

Jiye Shi

David Edward Knight

Georges Mairet- Coello

Alastair David Lawson

Christian Gilbert Wolff

The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.

Anti-alpha-synuclein antibodies

Computer-implemented methods of designing an antibody that will bind to a target epitope are disclosed. In one arrangement, the method comprises identifying one or more hotspot residues that will each bind to a corresponding one of one or more hotspot sites on the target epitope. Candidate antibody structures are selected from a database such that characteristic atoms within the antibody structure and hotspot characteristic atoms can be superimposed computationally with an averaged spatial deviation less than a predetermined threshold. A designed antibody is generated by replacing matching residues with different residues such that a predicted affinity is increased.

De novo antibody design

The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.

Antibodies comprising a polypeptide inserted in framework 3 region

Methods and associated apparatus involving designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising using information about non-bonding, intra-molecular or inter-molecular atom to atom contacts extracted from a database of biological macromolecules to identify favoured regions adjacent to the binding site for particular atom types and modifying a candidate ligand to increase the intersection between atoms of the candidate ligand and the favoured regions. One or more steps of the methods may be performed by a computer.

Obtaining an improved therapeutic ligand

The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Expression vector encoding antibody molecule which binds IL-17A and IL-17F

The present invention relates to Tau-binding antibodies and binding fragments thereof.

Tau-binding antibodies

Anti-alpha synuclein antibodies

The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.

Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R; A is a lipophilic, hydrophobic moiety; Ris a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstituted or substituted Cto Calkylene or alkenylene group, which is optionally interrupted by one or more &#x2014;NR&#x2014;, &#x2014;O&#x2014; or &#x2014;S&#x2014; linkages, Ris &#x2014;YC(R)(R)COR; and pharmaceutically acceptable salts or solvates thereof are useful as endosomolytic agents particularly for the delivery of nucleic acids useful in gene therapy. 

Endosomolytic agents for gene therapy

A Na1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Na1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

[object Object]

Growing community of inventors

Slough, United Kingdom

Terence Seward Baker